Literature DB >> 1107103

Treatment of spastic cerebral-palsied children with sodium dantrolene.

E Denhoff, S Feldman, M G Smith, H Litchman, W Holden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1107103     DOI： 10.1111/j.1469-8749.1975.tb04697.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN： 0012-1622            Impact factor:   5.449


× No keyword cloud information.
  4 in total

Review 1.  Spasticity and drug therapy.

Authors:  E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1987-10-16

Review 2.  Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-01       Impact factor: 9.546

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

4.  Dantrolene-Induced Hepatitis: A Rare Culprit in the PICU.

Authors:  Divij Pasrija; Shilpi Gupta; Amanda Hassinger
Journal:  J Pediatr Intensive Care       Date:  2020-06-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.